Cyxone AB

Jun 10, 2020

Cyxone Files New Patent Applications Following Additional Innovation Achievements

Nov 13, 2019

Kjell G. Stenberg Steps Down as CEO of Cyxone

Aug 29, 2019

Cyxone's CEO Kjell G. Stenberg Acquires Additional Shares in the Company

Aug 02, 2019

Cyxone's T20K Shows Favorable Safety and Tolerability in First-in-human Trial

Jul 19, 2019

Cyxone Makes Further Strides With Rabeximod Phase IIb Trial by Signing CRO EGeen Inc.

Jul 05, 2019

Cyxone Submits First Application to Start Clinical Phase IIb Trial With Rabeximod

Jun 20, 2019

Cyxone Initiates First-in-human Trial With T20K for the Treatment of MS

Feb 04, 2019

Cyxone Announces Issuance of U.S. Divisional Patent for Drug Candidate T20K in MS

Nov 28, 2018

Cyxone Concludes T20K's Preclinical Program Following Positive Results in Toxicology Studies

Oct 31, 2018

First Berlin Equity Research Publishes Independent Analysis of Cyxone

Oct 23, 2018

Cyxone Selects First Clinical Site Ahead of Phase 1 Study With T20K in MS